2025-03-18 IDOPRESS
HEFEI,China,March 17,2025 -- Sungrow Hydrogen has secured the largest share of the hydrogen production equipment contract for China Coal OrdosEnergy Chemical's "100,000-ton Liquid Sunshine" DemonstrationProject,a national green hydrogen flagship initiative. The company will deliver16 alkaline electrolyzers (1,200 Nm³/h each)and integrated gas-liquid separation and purification systems,reinforcing its leadership in large-scale industrial green hydrogen solutions.
The USD680 million projectintegrates renewables,hydrogen,and ESSto decarbonize coal-based industries. Key components include:
625 MWwind/solar power capacity
21,000 tons/yeargreen hydrogen production
100,000 tons/yearmethanol synthesis using CO₂ and green hydrogen
500,000 tons/yearCO₂ reduction upon completion.
As the core component of the project,SungrowHydrogen's flexible green hydrogen production system meets stringent requirements for continuous and stable operation,efficiently coupling with fluctuating renewable energy sources like solar and wind power. It enables large-scale green hydrogen production and the application validation of green hydrogen-to-methanol conversion,providing replicable low-carbon transition pathways for high-carbon industries such as coal chemical engineering,critical for commercial scalability.
With multiple large-scale green hydrogen projects advancing worldwide,Sungrow Hydrogen continues to drivethe global transitionfrom pilot demonstrations to industrial-scale green hydrogen adoption.
About Sungrow Hydrogen
A leader in water electrolysis hydrogen production technology,Sungrow Hydrogenempowers industries to achieve net-zero targets through innovative hydrogen solutions.
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM
©copyright 2009-2020 Singapore Info Map